Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218214 | 0.90 | LMNA (0.49) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL13601336 | 0.85 | BCHE (0.52) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL4454820 | 0.84 | LMNA (0.69) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL4464262 | 0.84 | BCHE (0.51) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL13601165 | 0.83 | TDP1 (0.70) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL14178233 | 0.83 | BCHE (0.50) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL7999502 | 0.81 | ESR1 (0.72) | LMNATSHRESR1CYP1A2CYP2C19 | |
| SCHEMBL14582344 | 0.81 | TDP1 (0.57) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL14178234 | 0.81 | ALDH1A1 (0.51) | BCHEACHELMNATSHRESR1 | |
| SCHEMBL6321099 | 0.80 | BCHE (0.48) | BCHEACHELMNATSHRESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452425-B2 | Compositions containing ionic liquids and their uses, in particular in organic synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9452425-B2 | Compositions containing ionic liquids and their uses, in particular in organic synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-09-27 | — | — | US | disclosed |
| US-20090326228-A1 | COMPOSITIONS CONTAINING IONIC LIQUIDS AND THEIR USES, IN PARTICULAR IN ORGANIC SYNTHESIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-31 | — | — | US | disclosed |
| US-20070043234-A1 | Use of functionalized onium salts as a soluble support for organic synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326228-A1 | COMPOSITIONS CONTAINING IONIC LIQUIDS AND THEIR USES, IN PARTICULAR IN ORGANIC SYNTHESIS | F12, ANXA1, F11 | BCHE 3512/4885ACHE 1854/4885LMNA 110/4885 |
| US-20070043234-A1 | Use of functionalized onium salts as a soluble support for organic synthesis | NOS1, NOS2, F12 | BCHE 3009/4885ACHE 748/4885LMNA 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.